Kiltearn Partners LLP Decreases Holdings in CVS Health Co. (NYSE:CVS)

Kiltearn Partners LLP cut its position in CVS Health Co. (NYSE:CVS - Free Report) by 9.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 716,868 shares of the pharmacy operator's stock after selling 74,800 shares during the quarter. CVS Health accounts for 6.1% of Kiltearn Partners LLP's portfolio, making the stock its 3rd largest position. Kiltearn Partners LLP owned 0.06% of CVS Health worth $45,077,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CVS. Assetmark Inc. lifted its position in shares of CVS Health by 9.7% during the third quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator's stock worth $25,781,000 after purchasing an additional 36,132 shares during the last quarter. Cullinan Associates Inc. grew its position in shares of CVS Health by 43.8% in the 3rd quarter. Cullinan Associates Inc. now owns 122,682 shares of the pharmacy operator's stock worth $7,125,000 after acquiring an additional 37,395 shares in the last quarter. Sompo Asset Management Co. Ltd. increased its holdings in shares of CVS Health by 8.4% in the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 134,523 shares of the pharmacy operator's stock valued at $8,459,000 after acquiring an additional 10,453 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new position in CVS Health during the second quarter worth $57,584,000. Finally, Oppenheimer Asset Management Inc. boosted its holdings in CVS Health by 5.7% in the third quarter. Oppenheimer Asset Management Inc. now owns 448,323 shares of the pharmacy operator's stock worth $28,191,000 after purchasing an additional 24,285 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Stock Performance

CVS traded up $0.76 during midday trading on Wednesday, reaching $59.77. The company's stock had a trading volume of 5,583,936 shares, compared to its average volume of 11,336,732. CVS Health Co. has a twelve month low of $52.71 and a twelve month high of $83.25. The stock has a market cap of $75.22 billion, a P/E ratio of 14.98, a PEG ratio of 1.01 and a beta of 0.55. The company has a fifty day simple moving average of $59.26 and a 200 day simple moving average of $58.69. The company has a current ratio of 0.80, a quick ratio of 0.59 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.01. The business had revenue of $95.43 billion during the quarter, compared to analysts' expectations of $92.72 billion. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The firm's revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the company earned $2.21 earnings per share. Research analysts expect that CVS Health Co. will post 5.43 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Monday, October 21st were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 4.45%. The ex-dividend date was Monday, October 21st. CVS Health's dividend payout ratio (DPR) is presently 67.51%.

Wall Street Analyst Weigh In

CVS has been the topic of a number of recent research reports. Mizuho reduced their price target on shares of CVS Health from $73.00 to $66.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Evercore ISI lifted their target price on CVS Health from $62.00 to $75.00 and gave the company an "outperform" rating in a research note on Tuesday, October 8th. UBS Group increased their price target on CVS Health from $60.00 to $62.00 and gave the stock a "neutral" rating in a research report on Thursday, November 7th. TD Cowen upped their price objective on CVS Health from $73.00 to $80.00 and gave the stock a "buy" rating in a research note on Monday. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $62.00 price objective on shares of CVS Health in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $70.33.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.